XML 18 R4.htm IDEA: XBRL DOCUMENT v3.25.2
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Revenue:        
Total revenue $ 86,679 $ 92,274 $ 171,364 $ 164,323
Operating expenses:        
Research and development 16,830 19,693 35,354 38,404
Sales and marketing 24,279 21,002 47,270 40,832
General and administrative 27,683 30,907 50,452 61,047
Litigation settlement expense 350 0 5,710 0
Total operating expenses 97,800 99,601 195,859 194,216
Loss from operations (11,121) (7,327) (24,495) (29,893)
Other income:        
Interest income, net 2,364 2,826 5,148 5,711
Other income (expense), net 72 (100) 367 (390)
Total other income 2,436 2,726 5,515 5,321
Loss before income taxes (8,685) (4,601) (18,980) (24,572)
Income tax benefit (expense) 117 (22) 59 61
Net loss $ (8,568) $ (4,623) $ (18,921) $ (24,511)
Net loss per share (Note 3):        
Basic (in usd per share) $ (0.16) $ (0.09) $ (0.35) $ (0.47)
Diluted (in usd per share) $ (0.16) $ (0.09) $ (0.35) $ (0.47)
Weighted-average shares used to compute net loss per share:        
Basic (in shares) 54,304,754 52,195,620 54,781,601 51,943,989
Diluted (in shares) 54,304,754 52,195,620 54,781,601 51,943,989
Testing services revenue        
Revenue:        
Total revenue $ 62,033 $ 70,918 $ 123,954 $ 124,755
Operating expenses:        
Cost of testing services, product, patient and digital solutions 15,406 14,308 30,519 27,940
Product revenue        
Revenue:        
Total revenue 11,833 10,610 22,643 19,204
Operating expenses:        
Cost of testing services, product, patient and digital solutions 4,981 6,298 10,567 11,642
Patient and digital solutions revenue        
Revenue:        
Total revenue 12,813 10,746 24,767 20,364
Operating expenses:        
Cost of testing services, product, patient and digital solutions $ 8,271 $ 7,393 $ 15,987 $ 14,351